Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: January 27, 2026
Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].
Journal: The journal of prevention of Alzheimer's disease
Published: June 06, 2025
Astrocytes provide a unique biomarker for Alzheimer's and other pathologies.
Journal: The journal of prevention of Alzheimer's disease
Published: June 02, 2025
Erratum to "INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(1): 100005.].
Journal: The journal of prevention of Alzheimer's disease
Published: June 01, 2025
Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: April 22, 2025
Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: November 26, 2024
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: October 16, 2024
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: September 06, 2024
Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: July 25, 2024
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: July 23, 2024
Revised criteria for the diagnosis and staging of Alzheimer's disease.
Journal: Nature medicine
Published: June 28, 2024
Last Updated: 09/26/2026